Wednesday, April 01, 2026

What Medicus Pharma Does #newsout #healthcareinnovation #biotechinvesting #medicuspharma

Mar 31, 2026

Beyond dermatologic oncology, Medicus is expanding its pipeline with Teverelix, a next-generation therapy targeting advanced prostate cancer and cardiovascular risk, along with additional studies in acute urinary retention. With multiple clinical catalysts ahead and ongoing FDA engagement, the company is positioning itself for continued growth in the biotech sector.

See the full interview here: https://youtu.be/C80cY55NAJA

Recommended

Who is Medicus Pharma? #newsout #biotechinvesting #healthcareinnovation #medicuspharma

Who is Medicus Pharma? #newsout #biotechinvesting #healthcareinnovation #medicuspharma

8 hours ago
Medicus Pharma Reports Breakthrough Skin Cancer Results and Expands Oncology Pipeline

Medicus Pharma Reports Breakthrough Skin Cancer Results and Expands Oncology Pipeline

8 hours ago
Medicus Pharma Reports Strong Phase 2 Results for Skinject in Skin Cancer Treatment

Medicus Pharma Reports Strong Phase 2 Results for Skinject in Skin Cancer Treatment

1 day ago
Virtuix Signs U.S. Navy Deal to Expand VR Military Training and Simulation | VTIX

Virtuix Signs U.S. Navy Deal to Expand VR Military Training and Simulation | VTIX

2 days ago
ACME Markets Launches Blockchain Lending Platform on Canton Network for Tokenized Assets

ACME Markets Launches Blockchain Lending Platform on Canton Network for Tokenized Assets

4 days ago
Vivos Expands Insurance Coverage for Sleep Apnea Treatment, Targets Profitability

Vivos Expands Insurance Coverage for Sleep Apnea Treatment, Targets Profitability

5 days ago
Open Page